JP3225012U - supplement - Google Patents
supplement Download PDFInfo
- Publication number
- JP3225012U JP3225012U JP2019003328U JP2019003328U JP3225012U JP 3225012 U JP3225012 U JP 3225012U JP 2019003328 U JP2019003328 U JP 2019003328U JP 2019003328 U JP2019003328 U JP 2019003328U JP 3225012 U JP3225012 U JP 3225012U
- Authority
- JP
- Japan
- Prior art keywords
- supplement
- salt
- gotu kola
- effect
- divalent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013589 supplement Substances 0.000 title claims abstract description 54
- 239000000126 substance Substances 0.000 claims abstract description 26
- 244000146462 Centella asiatica Species 0.000 claims abstract description 20
- 235000004032 Centella asiatica Nutrition 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 150000002505 iron Chemical class 0.000 claims abstract description 14
- 239000002775 capsule Substances 0.000 claims abstract description 9
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 claims abstract description 8
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 claims abstract description 8
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 claims abstract description 8
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000000465 moulding Methods 0.000 claims abstract description 3
- 235000015489 Emblica officinalis Nutrition 0.000 claims description 11
- 244000119298 Emblica officinalis Species 0.000 claims description 11
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 22
- 238000002156 mixing Methods 0.000 abstract description 11
- 230000009471 action Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000019485 Safflower oil Nutrition 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000003796 beauty Effects 0.000 description 5
- 235000013871 bee wax Nutrition 0.000 description 5
- 239000012166 beeswax Substances 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000005713 safflower oil Nutrition 0.000 description 5
- 239000003813 safflower oil Substances 0.000 description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000218998 Salicaceae Species 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 159000000014 iron salts Chemical class 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical compound [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 description 2
- 241000222501 Agaricaceae Species 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 240000000588 Hericium erinaceus Species 0.000 description 1
- 235000007328 Hericium erinaceus Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 description 1
- 241000208720 Nepenthes Species 0.000 description 1
- 235000001537 Ribes X gardonianum Nutrition 0.000 description 1
- 235000001535 Ribes X utile Nutrition 0.000 description 1
- 235000002357 Ribes grossularia Nutrition 0.000 description 1
- 244000171263 Ribes grossularia Species 0.000 description 1
- 235000016919 Ribes petraeum Nutrition 0.000 description 1
- 244000281247 Ribes rubrum Species 0.000 description 1
- 235000002355 Ribes spicatum Nutrition 0.000 description 1
- 241000647991 Salacia reticulata Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 1
- 229940011658 asiatic acid Drugs 0.000 description 1
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940022757 asiaticoside Drugs 0.000 description 1
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- -1 iron salt Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【課題】サプリメントを構成する各物質が有する作用の相乗効果に加え、各物質自体の効能を大巾に増強し得るサプリメントを提供する。【解決手段】ゴツコラ、アムラ、コタラヒムブツ、ジオスゲニン、ヤマブシタケを含有し、さらに、二価三価鉄塩を含有してサプリメントを製造する。サプリメントは、サプリメントに含有させるゴツコラその他の各物質２（有効成分）を油性混合液１に混入し、カプセル３形態に成型して構成する。二価三価鉄塩を含有させることにより、サプリメントを構成する各物質自体の有する効能を予期し得ないほど大巾に増強する。【選択図】図１An object of the present invention is to provide a supplement that can greatly enhance the efficacy of each substance in addition to the synergistic effect of the action of each substance constituting the supplement. A supplement is produced which contains Gotu Kola, Amla, Kotara Himbutu, Diosgenin, Yamabushitake, and further contains a divalent trivalent iron salt. The supplement is formed by mixing Gotu kola and other substances 2 (active ingredients) to be contained in the supplement into the oily mixture 1 and molding the mixture into a capsule 3 form. The effect of each substance constituting the supplement itself is greatly increased unexpectedly by including the divalent iron (III) salt. [Selection diagram] Fig. 1
Description
本考案は、多種の機能を有するサプリメント関する。さらに詳しくは、例えば健康促進機能、栄養補助機能、美容機能その他多種の機能ないし効果を有するサプリメント関する。 The present invention relates to a supplement having various functions. More specifically, the present invention relates to a supplement having various functions or effects such as a health promotion function, a nutrition support function, a beauty function, and the like.
従来、例えば美容機能を有するサプリメント（美容サプリメント）として、コラーゲン、ゴツコラ（ツボクサ）、及び海洋深層水を含有して構成したサプリメント（食品組成物）が提案されている（例えば、特許文献１参照）。 2. Description of the Related Art Conventionally, as a supplement having a beauty function (beauty supplement), for example, a supplement (food composition) including collagen, gotu kola (butterfly), and deep sea water has been proposed (for example, see Patent Document 1). .
特許文献１の食品組成物（美容サプリメント）によれば、ツボクサ、海洋深層水及びコラーゲンを併用することにより、それぞれの成分が有する作用により、肌の新陳代謝を高め、肌の老化を防止して美容効果を奏すると思われる。 According to the food composition (beauty supplement) of Patent Literature 1, the combined use of the spiderweed, deep ocean water, and collagen enhances the metabolism of the skin and prevents aging of the skin due to the action of each component, and beauty is achieved. It seems to be effective.
また、従来、例えば健康促進機能を有するサプリメント（健康食品）として、アムラにツボクサ（ゴツコラ）を加えて混合して調製した健康サプリメント（健康食品）が提案されている（例えば、特許文献２参照）。この特許文献２のサプリメントによれば、アムラとツボクサ（ゴツコラ）との相乗作用により、アムラの薬効成分の効果を高め、これにより健康促進効果を向上することが可能になると思われる。
Conventionally, as a supplement (health food) having a health promoting function, a health supplement (health food) prepared by adding Amla with a sponge (gotu kola) and mixing the same has been proposed (for example, see Patent Document 2). . According to the supplement of
特許文献１及び同２に記載のサプリメントによれば、それぞれ特性を有するサプリメント（文献１は食品組成物、文献２に健康食品）を得ることができる。
According to the supplements described in
しかし、特許文献１は、ツボクサ（ゴツコラ）、海洋深層水及びコラーゲンの各成分（物質）がそれぞれ元来有する作用の相乗作用（効果）を利用したものである。また、特許文献２についても、アムラ及びツボクサ（ゴツコラ）の各成分（物質）が元来的に有する作用の相乗作用を利用したものである。そのため、各成分自体の効果を向上させることは期待できない。
However, Patent Literature 1 utilizes a synergistic effect (effect) of each of the components (substances) of the spiderweed (gotu kola), deep sea water, and collagen.
本考案は上記したような実情に鑑みてなされたもので、サプリメントを構成する各物質（成分）が有する作用の相乗作用（効果）に加え、各物質自体の機能（効能）を予期し得ないほど大巾に向上し得るサプリメントを提供することを目的とするものである。 The present invention has been made in view of the above circumstances, and in addition to the synergistic action (effect) of the action of each substance (component) constituting the supplement, the function (efficacy) of each substance itself cannot be expected. It is an object of the present invention to provide a supplement that can be significantly improved.
本考案者は、上記課題を解決するために、研究、実験を続けた結果、その目的を達成したので、ここにその考案を提供する。 The present inventor has continued his research and experiments in order to solve the above-mentioned problems, and as a result has achieved the object. Therefore, the present invention is provided here.
即ち、本考案のうち、１つの考案（第１の考案）は、サプリメントであって、
ゴツコラ及び二価三価鉄塩を含有し、さらに、アムラ、コタラヒムブツ、ジオスゲニン及びヤマブシタケからなる群から選択した一種又は複数種を含有して構成したことを特徴とする。
That is, one of the inventions (first invention) is a supplement,
It is characterized by containing Gotu kola and a ferrous (III) iron salt, and further containing one or more selected from the group consisting of Amla, Kotarahimbutu, diosgenin and Yamabushitake.
本考案の他の１つの考案（第２の考案）は、サプリメントであって、ゴツコラ、アムラ、コタラヒムブツ、ジオスゲニン及びヤマブシタケを含有し、さらに、二価三価鉄塩を含有して構成したことを特徴とする。 Another invention (second invention) of the present invention is a supplement, which contains Gotu kola, Amla, Kotarahimbutu, diosgenin and Yamabushitake, and further contains a divalent ferric salt. It is characterized by.
本考案のさらに他の１つの考案（第３の考案）は、第２の考案のサプリメントにおいて、さらに亜鉛を含有して構成したことを特徴とする。 Yet another invention (third invention) of the present invention is characterized in that the supplement of the second invention is configured to further contain zinc.
本考案において、前記サプリメントはカプセルの形態に成型する構成を採用することができる。 In the present invention, the supplement may be formed into a capsule.
本考案において、前記サプリメントに含有させる前記ゴツコラその他の各物質は、油性混合液に混合されてカプセルの形態に成型する構成を採用することができる。 In the present invention, it is possible to adopt a configuration in which the Gotu kola and other substances to be contained in the supplement are mixed with an oily mixture and molded into a capsule form.
前記ゴツコラ（gotukola）は「ゴツクラ」とも称され、日本ではツボクサ（centella asiatica：センテラ アジアティカ）として知られているハーブである。 The said gotu kola (gotukola) is also called "gotsukura" and is an herb known in Japan as Centella asiatica (centella asiatica).
ゴツクラ（ツボクサ）は、インドの伝統医学アーユルヴェーダで、古くからハンセン氏病などの感染による皮膚のただれや、潰瘍の治療薬として使用されてきた。その他にも、血行促進、血液浄化、免疫力の向上、知能向上、記憶力の向上効果など数多くの用途で使用されている。その成分としては、マデカソサイド、アジアチコサイド、アジアチン酸、マデカシン酸等のトリテルペン類、サボニゲン類などが確認されている。ゴツクラ（ツボクサ）は、バングラデシュ、タイ、スリランカでは、葉野菜として食されており、安全性については問題がないと考えられる。 Gotukra is a traditional Indian medicine in Ayurveda that has long been used as a treatment for skin soreness and ulcers caused by infections such as Hansen's disease. In addition, it is used for many purposes such as blood circulation promotion, blood purification, immunity improvement, intelligence improvement, and memory improvement effect. As the components, triterpenes such as madecasoside, asiaticoside, asiatic acid and madecasic acid, savonigenes and the like have been confirmed. Gotukra is a leafy vegetable in Bangladesh, Thailand and Sri Lanka, and is considered to have no safety issues.
アムラ（学名：pbyllanthus emblica）はコミカンソウ科の落葉性の小高木で、「インドスグリ」とも呼ばれている。サンスクリット語では「看護姉」との意味から「アーマラキー」、英語では「インディアングーズベリー」とも表記される。 Amla (scientific name: pbyllanthus emblica) is a deciduous small tree of the family Citrus family and is also called "Indo currant". In Sanskrit, it is also called "Armaraki" because of "nursing sister", and in English it is also called "India Gooseberry".
アムラは、糖尿病や高血圧を予防する効果、コレステロール値を下げる効果、美肌効果、便秘改善、貧血予防、ストレスの抵抗力を高める効果、白髪や脱毛を予防する効果等の効果を有している。 Amla has effects such as an effect of preventing diabetes and hypertension, an effect of lowering cholesterol level, a beautiful skin effect, improvement of constipation, anemia prevention, an effect of increasing stress resistance, an effect of preventing gray hair and hair loss, and the like.
コタラヒムブツ（学名：Salacia reticulata）は、ニシキギ目ニシギキ科サラシア属のつる性植物で、糖尿病の予防効果を有し、インドのアーユルベーダでは、糖尿病の治療薬として用いられ、その効果はWHOで２００２年に認められている。 Kotarahimbutu (scientific name: Salacia reticulata) is a climbing plant belonging to the genus Salicaceae belonging to the genus Salicaceae, and has a preventive effect on diabetes. Has been recognized.
ジオスゲニンは、ヤマイモに含まれる天然成分で、滋養強壮に良い伝統生薬として古くから用いられ、抗ガン作用、食物アレルギー改善、アンチエイジング効果、ダイエット効果などの諸効能があることで知られている。 Diosgenin is a natural ingredient contained in yam and has been used for a long time as a traditional herbal medicine with good nutrition and tonicity, and is known to have various effects such as anti-cancer effect, food allergy improvement, anti-aging effect and diet effect.
ヤマブシタケ（学名：Hericium erinaceus）は、サンゴハリタケ科サンゴハリタケ属の食用キノコの一種で、認知症治療にも注目されている。ヤマブシタケに含まれる成分の「ヘリセノン」は、認知症の特効薬として近年注目されている。その他にも感染症、循環器、消化器、内分泌などにさまざまな効果が期待されている。 Yamabushitake (scientific name: Hericium erinaceus) is a type of edible mushroom belonging to the genus Coralum agaricaceae, and has also attracted attention in the treatment of dementia. “Helicenone”, a component contained in Yamabushitake, has recently attracted attention as a specific drug for dementia. In addition, various effects are expected for infectious diseases, cardiovascular, digestive, endocrine, and the like.
亜鉛は、ヒトの体内に必須のミネラル１６種の中１種で、味覚を正常に保つ。抗酸化作用を活性化する。免疫力を向上させる。発育や成長のサポートをする。そのほか、肌や髪を綺麗に保つ効果が期待されていると共にうつ状態の緩和に効果があると考えられている。 Zinc is one of the 16 essential minerals in the human body and maintains normal taste. Activates antioxidant action. Improve immunity. Support growth and growth. In addition, it is expected to have an effect of keeping skin and hair clean, and is also considered to be effective in alleviating depression.
二価三価鉄塩は近年開発された活性物質で、この活性物質（二価三価鉄塩）は二価鉄と三価鉄との中間の性質を示す単一の化合物、或いは二価鉄と三価鉄が共存する単一の化合物であると思われる。この二価三価鉄塩は現在工業的に生産可能である（例えば、特公平３−６３５９３号公報、特公平４−２７１７１号公報参照）。 Ferrous ferrous salt is a recently developed active substance, which is a single compound that exhibits properties intermediate between ferrous and ferrous iron, or ferrous iron And iron (III) are considered to be a single compound. This divalent and trivalent iron salt can be industrially produced at present (see, for example, Japanese Patent Publication Nos. 3-63593 and 4-27171).
二価三価鉄塩としては、例えば、下記式、
Ｆｅ+２ ｍＦｅ＋３ ｎＣｌ２ｍ＋３ｎ（式中ｍ及びｎは正の整数を示す）
で示される化合物が例示できる。
As the divalent and trivalent iron salt, for example, the following formula,
Fe +2 m Fe +3 n Cl 2m + 3n (m and n in the formula is a positive integer)
Can be exemplified.
前記二価三価鉄塩は、例えば塩化第二鉄を水酸化ナトリウム，水酸化カルシウム，水酸化カリウム，水酸化リチウム等の強アルカリの水溶液に投入して原子価変換を起こさせた場合の遷移形態等として得られる（第１の方法）。この第１の方法による具体的製造方法として、例えば次の工程により得たものを例示する。即ち、塩化第二鉄を強アルカリの水溶液に溶解させる工程、この溶液を中和する工程、この中和した溶液を濃縮する工程、とを含んで製造する。 The divalent and trivalent iron salt is, for example, a transition when ferric chloride is introduced into an aqueous solution of a strong alkali such as sodium hydroxide, calcium hydroxide, potassium hydroxide, and lithium hydroxide to cause valence conversion. It is obtained as a form or the like (first method). As a specific manufacturing method according to the first method, for example, a method obtained by the following steps is exemplified. That is, the production is performed including a step of dissolving ferric chloride in an aqueous solution of a strong alkali, a step of neutralizing the solution, and a step of concentrating the neutralized solution.
また、二価三価鉄塩は、三価の鉄塩と二価の金属塩とを混合した溶液によっても得られる。具体的には、例えば三価の鉄塩及び二価の金属塩を所定の比率で含有する所定濃度の希薄水溶液に、第二鉄塩を添加して溶解させ、得られた溶液を濃縮して製造することができる（第２の方法）。前記第二鉄塩としては、例えば塩化第二鉄、硫酸第二鉄、硝酸第二鉄を用いることができる。前記二価の金属塩としては、例えば塩化カルシウム，塩化マグネシウム，塩化亜鉛，硫酸マグネシウム，硝酸カルシウム，硝酸マグネシウム，硝酸亜鉛を用いることができる。 Further, the divalent and trivalent iron salt can be obtained by a solution in which a trivalent iron salt and a divalent metal salt are mixed. Specifically, for example, a ferric salt is added to and dissolved in a dilute aqueous solution of a predetermined concentration containing a trivalent iron salt and a divalent metal salt at a predetermined ratio, and the obtained solution is concentrated. It can be manufactured (second method). As the ferric salt, for example, ferric chloride, ferric sulfate, and ferric nitrate can be used. Examples of the divalent metal salt include calcium chloride, magnesium chloride, zinc chloride, magnesium sulfate, calcium nitrate, magnesium nitrate, and zinc nitrate.
前記二価三価鉄塩の前記式中のｍ：ｎの比は前記化合物製造に用いる物質の種類等により特定の数値をとる。 The ratio of m: n in the above formula of the divalent and trivalent iron salt takes a specific numerical value depending on the kind of the substance used in the production of the compound and the like.
前記二価三価鉄塩は、サプリメントを構成するゴツクラ（ツボクサ）その他の各物質が有する前記作用（効能）を大巾に増強する。したがって、例えば油性混合液中にゴツクラその他の各物質を混合し、これに前記二価三価鉄塩を添加混合することにより、前記各物質の有する機能（作用）を増強する。前記二価三価鉄塩は極く少量添加することにより、上記作用を発揮する。この成果は本考案者らによる実験により判明されている。本考案のサプリメントは、主に内服剤として用いられる。 The divalent and trivalent iron salt greatly enhances the above-mentioned action (efficacy) of gotsukura (brown box) and other substances constituting the supplement. Therefore, for example, the functions (actions) of the respective substances are enhanced by mixing, for example, gotsukura and other substances in an oily liquid mixture, and adding and mixing the divalent and trivalent iron salts thereto. The above-mentioned effect is exerted by adding a very small amount of the above-mentioned ferric salt. This result has been found through experiments by the present inventors. The supplement of the present invention is mainly used as an internal medicine.
本考案によれば、サプリメントを構成するゴツクラ（ツボクサ）その他の各物質（成分）が有する作用の相乗作用（効果）に加え、各物質自体の機能（効能）を予期し得ないほど大巾に増強し得るサプリメントを提供することができる。 According to the present invention, in addition to the synergistic action (effect) of the action of each of the substances (components), such as gotukra (muckweed), which constitute the supplement, the function (efficacy) of each substance itself is unpredictably large. A supplement that can be enhanced can be provided.
以下、図面を参照して本考案のサプリメントの実施形態の一例について説明する。 Hereinafter, an example of an embodiment of the supplement of the present invention will be described with reference to the drawings.
本実施形態のサプリメントは、油性混合液１にサプリメントを構成（調製）する各物質（サプリメントの有効成分）２を混合し、カプセル３の形態に成型して構成した例が開示されている。
The supplement of this embodiment discloses an example in which a substance (active ingredient of the supplement) 2 constituting (preparing) the supplement is mixed with an oily mixed liquid 1 and molded into a
本実施形態の油性混合液は、サフラワー油、乳化剤、及びミツロウを採用している。サフラワー油、乳化剤、及びミツロウの配合割合は特に限定するものではないが、例えば、重量比でサフラワー油に対し、乳化剤を約７〜約８ｗ％、ミツロウを約７〜約８ｗ％程度の範囲を採用できる。 The oily mixture of the present embodiment employs safflower oil, an emulsifier, and beeswax. The mixing ratio of the safflower oil, the emulsifier, and the beeswax is not particularly limited. For example, about 7 to about 8 w% of the emulsifier and about 7 to about 8 w% of the beeswax with respect to the weight of the safflower oil. A range can be adopted.
サプリメントの構成物質（成分）２としては、ゴツコラ、アムラ、コタラヒムブツ、ジオスゲニン（ヤマイモ抽出物）、ヤマブシタケ、亜鉛及び二価三価鉄塩を採用している。前記ゴツコラその他の各物質（成分）は粉粒状（粉末ないし顆粒状）に形成されている。 As the constituent substance (component) 2 of the supplement, gotu kola, amla, kotara himbutu, diosgenin (yama extract), yamabushitake, zinc, and ferric (III) iron salt are employed. The above-mentioned Gotu kola and other substances (components) are formed in a powder form (powder or granular form).
サプリメントの前記構成成分の配合割合は特に限定するものではないが、サプリメントの全量に対し、例えばゴツコラ約１６．０：アムラ約１０．０：コタラヒムブツ約１６．０：ジオスゲニン約１６．０：ヤマブシタケ約８．０：亜鉛約０．７：二価三価鉄塩約２．５程度（サプリメントの全量約６９．２）の範囲を挙げることができる。 Although the mixing ratio of the above-mentioned components of the supplement is not particularly limited, for example, about 16.0 of Gotu Kola: about 10.0 of Amla: about 16.0 of Kotara Himbutu: about 16.0 of diosgenin: 16.0: Yamabushitake with respect to the total amount of the supplement A range of about 8.0: zinc about 0.7: about divalent trivalent iron salt about 2.5 (the total amount of the supplement is about 69.2).
サプリメントの製造方法としては、例えば図２（ａ）に示すように、所望の大きさ及び形状の容器に油性混合液１を充填し、図２（ｂ）に示すように、サプリメントを構成する各物質（粉粒体）２を油性混合液１中に入れて混合し、常法によりカプセル形態に成型して構成する。本実施形態ではソフトカプセル形態に成型した例が開示されている。 As a method for producing the supplement, for example, as shown in FIG. 2A, a container having a desired size and shape is filled with the oil-based mixed solution 1, and as shown in FIG. A substance (powder or granular material) 2 is put in the oil-based mixed liquid 1, mixed, and formed into a capsule by a conventional method. In the present embodiment, an example of molding into a soft capsule form is disclosed.
上記により製造したカプセル形態のサプリメントは内服剤として用いられる。これにより、上述した作用効果を奏する。 The supplement in the form of a capsule produced as described above is used as an oral preparation. Thereby, the above-described effects can be obtained.
なお、油性混合液１に対する前記物質（成分）２の配合割合は特に限定するものではなく、適当に設定できるものであるが、例えば、油性混合液１に対し、前記物質２（全量）を約１／３程度の範囲を挙げることができる。 The mixing ratio of the substance (component) 2 to the oily mixture 1 is not particularly limited and can be appropriately set. For example, the amount of the substance 2 (total amount) is about A range of about 1/3 can be mentioned.
（実施例）
次に本考案の実施例を説明する。下記実施例はその一例として開示したもので、本考案はこれら限定されるものではないこと勿論である。
(Example)
Next, an embodiment of the present invention will be described. The following embodiments are disclosed as examples, and the present invention is not limited to these embodiments.
下記実施例では二価三価鉄塩として、下記により製造したものを採用した。 In the following examples, those produced as described below were employed as the divalent and trivalent iron salts.
１．０ｍｇの塩化第二鉄を１００ｍｌの０．５Ｎカセイソーダ水溶液に入れ、攪拌溶解させて２４時間静置する。前記溶液中に生じた不溶性物質を除去し、この溶液を塩酸で中和した後、減圧濃縮してデシケーター中で乾燥結晶化する。得られた結晶に５０ｍｌのイソプロピルアルコール８０重量％水溶液を加えて再溶解し、減圧濃縮して溶媒を除去、乾燥させ、この再溶解，濃縮，乾燥を数回繰り返すことにより０．２５ｍｇの結晶を得た。この結晶を水（蒸留水又は純水）に溶解して約１００倍〜約１０，０００倍に希釈した水溶液、即ち、前記二価三価鉄塩約０．０１％〜約１％水溶液（二価三価鉄塩の原液）とする。そして、前記原液を粉末化して二価三価鉄塩を製造し、この粉末状の二価三価鉄塩を使用する。 1.0 mg of ferric chloride is added to 100 ml of 0.5N aqueous sodium hydroxide solution, dissolved by stirring, and allowed to stand for 24 hours. After removing the insoluble substance generated in the solution, the solution is neutralized with hydrochloric acid, concentrated under reduced pressure, and dried and crystallized in a desiccator. The obtained crystals were re-dissolved by adding 50 ml of an 80% by weight aqueous solution of isopropyl alcohol, concentrated under reduced pressure to remove the solvent, and dried. The re-dissolution, concentration and drying were repeated several times to obtain 0.25 mg of the crystals. Obtained. The crystals were dissolved in water (distilled water or pure water) and diluted about 100 to about 10,000 times, that is, about 0.01% to about 1% aqueous solution of the above-mentioned ferric salt (2). (Undiluted solution of trivalent iron salt). Then, the stock solution is powdered to produce a ferrous (III) salt, and the powdered ferric (III) salt is used.
本実施例は、下記表のNo.１ないしNo.３のサフラワー油、乳化剤、及びミツロウを混合して油性混合液１を調製し、この油性混合液に下記表のNo.４ないしNo.１０の各物質（粉粒状）を混合し、ソフトカプセルの形態に成型したサプリメントを採用した。なお、下記表１に示す原料の分量はサプリメント１粒あたりの分量（単位：ｇ）を示す。 In this example, an oily mixture 1 was prepared by mixing the safflower oils No. 1 to No. 3 in the following table, an emulsifier, and beeswax, and the oily mixture was mixed with No. 4 to No. 4 in the following table. A supplement was prepared by mixing each of the 10 substances (in the form of powder) into a soft capsule. The amounts of the raw materials shown in Table 1 below indicate the amount (unit: g) per one supplement.
（評価試験）
上記表１に基づいて製造したサプリメントを４０〜６０代の男女の被験者（１０名）に対して１日３粒づつ１０日間摂取（飲用）させ、投与前後における状態変化について調査した。その結果、比較例１及び２に比べ実施例１及び２のサプリメントの方が効果が大巾に向上することが判明した。特に疲労回復、記憶力の向上、美肌効果について、予期し得ないほど効果が増強することが判明した。これにより、二価三価鉄塩は優れた作用効果を発揮することが確認された。
(Evaluation test)
Male and female subjects in their 40s and 60s (10 subjects) were ingested (drinked) three tablets per day for 10 days, and the state change before and after administration was investigated. As a result, it was found that the effects of the supplements of Examples 1 and 2 were significantly improved as compared with Comparative Examples 1 and 2. In particular, it has been found that the effects of recovering fatigue, improving memory, and improving skin beautifulness are unexpectedly enhanced. Thereby, it was confirmed that the divalent and trivalent iron salt exerts an excellent effect.
なお、上記した実施形態及び実施例は一例として開示したもので、本考案は上記の実施形態及び実施例に限定されるものではなく、実用新案登録請求の範囲に記載の技術思想を越脱しない範囲内において任意に変更可能なものである。 It should be noted that the above-described embodiments and examples are disclosed as examples, and the present invention is not limited to the above-described embodiments and examples, and does not depart from the technical idea described in the utility model registration claims. It can be arbitrarily changed within the range.
１ 油性混合液
２ サプリメントを構成する物質（有効成分）
３ カプセル
４ 容器
1
3
本実施例は、下記表のNo.１ないしNo.３のサフラワー油、乳化剤、及びミツロウを混合して油性混合液１を調製し、この油性混合液に下記表のNo.４ないしNo.１０の各物質（粉粒状）を混合し、ソフトカプセルの形態に成型したサプリメントを採用した。なお、下記表１に示す原料の分量はサプリメント１粒あたりの分量（単位：ｍｇ）を示す。
In this example, an oily mixture 1 was prepared by mixing No. 1 to No. 3 safflower oil, an emulsifier, and beeswax in the following table, and this oily mixture was mixed with No. 4 to No. A supplement was prepared by mixing each of the 10 substances (in the form of powder) into a soft capsule. Incidentally, amount of raw materials shown in Table 1 below quantity per grain supplements (unit: m g) shows a.
Claims (5)
ことを特徴とするサプリメント。 It contains Gotu kola and a ferrous (III) iron salt, and further comprises one or more selected from the group consisting of Amla, Kotarahimbutu, diosgenin and Yamabushitake,
A supplement characterized by the following.
ことを特徴とするサプリメント。 It contains Gotu Kola, Amla, Kotara Himbutu, Diosgenin and Yamabushitake, and further contains a divalent iron (III) salt,
A supplement characterized by the following.
さらに、亜鉛を含有して構成したことを特徴とするサプリメント。 The supplement of claim 2,
Furthermore, a supplement characterized by containing zinc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019003328U JP3225012U (en) | 2019-09-03 | 2019-09-03 | supplement |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019003328U JP3225012U (en) | 2019-09-03 | 2019-09-03 | supplement |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP3225012U true JP3225012U (en) | 2020-02-06 |
Family
ID=69233005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019003328U Active JP3225012U (en) | 2019-09-03 | 2019-09-03 | supplement |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3225012U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115212245A (en) * | 2021-04-20 | 2022-10-21 | 木岛庆昌 | Composition and capsule and tablet containing the same |
| US11744854B2 (en) | 2019-11-19 | 2023-09-05 | Yoshimasa Kijima | Composition comprising natural extracts and an iron salt |
-
2019
- 2019-09-03 JP JP2019003328U patent/JP3225012U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11744854B2 (en) | 2019-11-19 | 2023-09-05 | Yoshimasa Kijima | Composition comprising natural extracts and an iron salt |
| CN115212245A (en) * | 2021-04-20 | 2022-10-21 | 木岛庆昌 | Composition and capsule and tablet containing the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3225012U (en) | supplement | |
| CN108938501A (en) | Chinese medicine composition and oral care product applied to oral care product | |
| CN101822736A (en) | Novel biological bactericide and preparation method thereof | |
| CN103421610B (en) | Preparation method of essence containing natural blueberry extract and toothpaste containing essence | |
| KR101415963B1 (en) | Cosmetic Composition | |
| CN101991132A (en) | Natural vitamin E soft capsule capable of being orally and externally used | |
| CN103271353B (en) | Liver protecting and health care composition and preparation method thereof | |
| CN106822579A (en) | Composition with treatment osteoporosis effect and its preparation method and application | |
| KR20200118322A (en) | Cleanser for women and methods for manufacturing the same | |
| CN101972449A (en) | Chinese medicinal material earthworm enzyme and peptide compound preparation and preparation method thereof | |
| JP2007014281A (en) | Liquid food composition ingestible by spraying and method for producing the same | |
| DE102014118772B4 (en) | Dietary supplement in capsule form containing Chinese medicinal mushrooms and their use | |
| CN107412620A (en) | Oral care composition | |
| RU2664838C1 (en) | Complex food additive and method of its use | |
| KR100488511B1 (en) | Health supplement including nature medicine ingredients and the composition thereof. | |
| CN105231457A (en) | Healthcare food enhancing immunity of human body and preparing method thereof | |
| KR101078765B1 (en) | Edible composition for prevention of periodontal disease by growth of bacteria in the mouth | |
| JP2002238496A (en) | Medical health food | |
| RU2177797C1 (en) | Biologically active supplement to increase male potency and method for its obtaining | |
| CN103947816A (en) | Selenium-rich chewing gum | |
| CN104255954A (en) | Abelmoschus manihot(L.) Medic. compound base seed oil and preparation method and application of abelmoschus manihot(L.) Medic. compound base seed oil | |
| CN107692208A (en) | A kind of queen bee Maca tablet and preparation method | |
| KR101195455B1 (en) | The composition of the pill-type anchovy and manufacturing process of the same | |
| CN1124138C (en) | Male silkmoth capsule and its preparing process | |
| KR20030087762A (en) | healthy cadence foodstuffs and that composion for increaing woman vitality |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191126 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 3225012 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |